Seeking men and women 18 years or older with non-cystic fibrosis bronchiectasis to participate in a study of the efficacy, safety, and tolerability of Brensocatib, administered once daily for 52 weeks.
We are studying the effects of an oral drug named Brensocatib, its safety, how well it works, and how well it is tolerated, for patients who have non-cystic fibrosis bronchiectasis. Participants can expect approximately 8 clinic visits and 4 telephone visits over approximately 62 weeks.
What we're hoping for
To evaluate the effect of brensocatib compared with a placebo on the rate of pulmonary exacerbation over the 52-week treatment period.
ClinicalTrials.gov Identifier: NCT04594369